PRO 140
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Template:Infobox drug/mab source |
| Target | CCR5 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ATC code | none |
PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection.[1]
The United States Food and Drug Administration has designated PRO 140 for fast-track approval.[2] In February 2008, the drug entered Phase 2 clinical trials.[3]
Development
PRO 140 is being developed by Progenics Pharmaceuticals. In May 2007, they announced results from the phase I clinical trial of the drug. The researchers said the results demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. Participants in the highest dosing group received 5 mg/kg and showed an average viral load decrease of -1.83 log10. On average, reductions of greater than -1 log10 copies/ml were maintained for between two and three weeks, from only a single dose of the drug.[4] The largest individual HIV RNA reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses.[5]
Mechanism of action
PRO 140 functions as an entry inhibitor.[6][7] PRO 140 binds to the CCR5 receptor, and interferes with HIV's ability to enter the cell. Unlike other entry inhibitors, PRO 140 is a monoclonal antibody. As such, it must be injected to be effective. However, once inside the body, PRO 140 binds to CCR5 for >60 days,[1] which may allow for dosing as infrequently as every other week.[8][9]
See also
External links
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 50px | This antiinfective drug article is a stub. You can help ssf by expanding it. |
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation. Press release, 22 Feb 2006. Progenics Pharmaceuticals.
- ↑ Brian Lawler. Progenics' Intriguing Study Results. The Motley Fool. 2 May 2007.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Derek Thaczuk. ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody. AIDSmap.com. 21 Sept 2007.
- ↑ Liz Highleyman. Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study. 28 Sept 2007. HIVandHepatitis.com
- ↑ Biswas P, Tambussi G, Lazzarin A (2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opin Pharmacother. 8 (7): 923–33. doi:10.1517/14656566.8.7.923. PMID 17472538.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ PRO 140. Progenics Pharmaceuticals.
- ↑ Tim Horn. Single-Dose PRO 140 Has Lasting Effects. 21 Sept 2007. POZ.com.
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Entry inhibitors
- Pages with broken file links
- Antiinfective agent stubs
- Monoclonal antibody stubs
- CS1 maint: Multiple names: authors list
